Currently, more than 185 million people worldwide are infected with hepatitis C virus (HCV), with a higher proportion in kidney transplant recipients (KTRs). 1 The prevalence of detectable anti-HCV antibodies among KTRs falls within the range of 1.8%-30% in Western countries 2 and is as high as 4. 4 HCV infection is a significant cause of liver dysfunction in KTRs, resulting in an increased incidence of cirrhosis, ascites, and hepatocarcinoma as well as extrahepatic manifestations, such as cryoglobulinemic vasculitis, recurrent membranous nephropathy, membranoproliferative glomerulonephritis, and transplant glomerulopathy.
| INTRODUC TI ON
Currently, more than 185 million people worldwide are infected with hepatitis C virus (HCV), with a higher proportion in kidney transplant recipients (KTRs). 1 The prevalence of detectable anti-HCV antibodies among KTRs falls within the range of 1.8%-30% in Western countries 2 and is as high as 4.2%-46.3% in China. 3, 4 HCV infection is a significant cause of liver dysfunction in KTRs, resulting in an increased incidence of cirrhosis, ascites, and hepatocarcinoma as well as extrahepatic manifestations, such as cryoglobulinemic vasculitis, recurrent membranous nephropathy, membranoproliferative glomerulonephritis, and transplant glomerulopathy. 5, 6 The combination of pegylated interferon (IFN) and ribavirin was the standard of care for HCV infection in previous decades. However, IFNbased treatment is rarely effective for KTRs, because it is associated with acute/chronic rejection, proteinuria, and a high drop-out rate. 7 IFN-based treatment may also worsen any pre-existing glomerular lesions. The availability of direct-acting antivirals (DAAs) has revolutionized the treatment of HCV infection based on the combination of two or three DAAs from different classes (NS5B polymerase inhibitors, NS5A
replication complex inhibitors and NS3/4A protease inhibitors). 8 The
European Association for the Study of liver recommends solid organ transplant recipients should be treated with the combination of sofosbuvir and ledipasvir or with the combination of sofosbuvir and velpatasvir, without the need for immunosuppressant drug dose adjustment. 9 Some studies have shown that DAAs can yield a 91%-100% sustained virological response 12 weeks after treatment (SVR12) in KTRs without increasing renal damage. [10] [11] [12] [13] [14] Different DAAs are increasingly being used for HCV treatment, of which one of the most commonly used regimens is sofosbuvir-daclatasvir. The aim of this study was to evaluate the efficacy and safety of sofosbuvir-daclatasvir in Chinese KTRs.
| MATERIAL S AND ME THODS

| Patients and study design
In this retrospective, non-interventional, single-center study, patients were identified by searching medical records from the kidney transplant registry system and the hospital laboratory 
| Efficacy assessments
The patients were followed up and monitored every 1-4 weeks dur- not corrected to the liver fibrosis stage. 16 The plasma HCV concentration was measured using COBAS AmpliPrep/COMBAS Taqman (Roche Molecular Systems, CA) real-time polymerase chain reaction-based assays with a lower limit of quantification of less than 15 IU/mL.
| Safety assessments
Signs and symptoms that occurred during DAA treatment and physical examinations were recorded by investigators during scheduled clinic visits. Serious adverse events were defined as any clinical manifestations requiring hospitalization or leading to the termination of antiviral therapy or those that were considered serious based on the judgment of the nephrologists.
| Outcomes
The main treatment goal was defined as SVR12, which was previously shown to predict a permanent cure for HCV infection. 17 The secondary end points included the incidence of adverse events, changes in hepatic and renal function and proteinuria.
| Statistical analysis
The baseline characteristics of the patients were described using the 
| RE SULTS
| Patient characteristics
Nineteen KTRs who received sofosbuvir-daclatasvir were enrolled in this study. The demographics and baseline characteristics of the patients are presented in Table 1 . The patients included 13 males and six females with a mean age 48.3 ± 9.6 years. Most patients (n = 17) were treatment naive, except for 2 patients who had pre- ) IU/mL in the study population. Three patients had a FIB-4 score greater than 3.25, and no clinical decompensated fibrosis was identified.
| Therapy and efficacy
Seventeen patients were treated for 12 weeks and 2 patients for 24 weeks. Quick HCV suppression was observed in the first week of treatment. Eighteen patients had a rapid virological response at 4 weeks, and 100% had undetectable viral loads at 12 weeks. All 19 patients were sequentially followed up for at least 12 weeks. In total, 100% of the patients achieved SVR12. For patients (n = 16) with available data at one year after therapy, HCV RNA remained Altogether, no significant differences in the eGFR and serum creatinine concentration were observed for the 19 patients before and after antiviral therapy (P = 0.07 and P = 0.28, respectively) ( Figure 2 ).
Specifically, increased serum creatinine levels were observed in 4 patients after treatment, whereas reduced levels were observed in 1 patient (defined as a greater than 20% difference from baseline).
| Safety and tolerability
Generally, all of the patients tolerated the antiviral treatment well.
The study population showed no premature treatment discontinuation and no serious adverse events requiring hospitalization during antiviral treatment. Common adverse events (fatigue, headache, rash, and diarrhea) that developed during the therapy disappeared a few days later with no additional treatment.
| Proteinuria
Proteinuria was assessed at each clinic visit. Eleven patients had proteinuria of more than 0.3 g/g at baseline, and 1 patient developed proteinuria during treatment. For the patients with proteinuria (n = 12), significant improvement was reported from 0.95 (0.35-3.31)
g/g at baseline to 0.39 (0.27-1.02) g/g after treatment (P = 0.048).
Among these patients, 8 patients had an improvement in proteinuria, two showed deterioration and two remained stable (defined as a less than 10% difference from baseline) (Figure 3) . 13 Prior to initiating antiviral therapy, four of the 12 patients had proteinuria higher than F I G U R E 1 Mean liver function parameters over time. ALT, alanine aminotransferase; AST, aspartate aminotransferase. *P < 0.05, **P < 0.05, ***P < 0.005, ns, not significant borderline changes with partial foot process effacement on electron microscopy. Patient 3 was diagnosed with chronic ABMR and mild interstitial fibrosis, and patient 4 had borderline changes and glomerulosclerosis. The doses of tacrolimus, mycophenolate mofetil, and prednisone were increased for the latter 3 patients. More detailed clinical information describing patients with biopsies are shown in Table S1 .
| Immunosuppression
The entire cohort received two or more immunosuppressive agents.
The most common combination was tacrolimus-mycophenolatesteroids (n = 13), followed by tacrolimus-steroids (n = 3) and cyclosporin-mycophenolate-steroids (n = 3). When treated with DAAs, the majority of the patients had a stable calcineurin inhibitor level (Figure 4 ).
| Outcomes compared with those of the chronic active hepatitis B group
The results showed that 8 patients were coinfected with HBV and HCV. The subgroups of coinfected HBV/HCV patients were investigated to determine whether the coinfection caused a poorer virological response and/or liver function. No significant differences were found in demographics, baseline platelet counts, and viral loads between the HBV-/HCV+ and HBV+/HCV+ groups ( Table   S2 ). The numbers of patients with a FIB-4 score greater than 3.25
were similar between the two groups. Before treatment, no differences were observed in liver function between the two groups After treatment, the hepatic function ameliorated in both groups, and the ALT and AST levels showed no differences between the groups (P = 0.82 and P = 0.52, respectively). Although the serum creatinine concentration and eGFR remained stable after therapy, Table S3 .
| D ISCUSS I ON
Hepatitis C virus infection is an important cause of hepatic dysfunction in KTRs. The combination of pegylated IFN and ribavirin was the standard of care for HCV infection for the last two decades.
However, its clinical application was limited in graft recipients because of severe hematologic side effects and potential rejection due to the immune modulation effect of IFN. 7 The emergence of newly developed DAAs has lessened these treatment constraints.
Recent studies have examined DAA-based treatment in the post-kidney transplant population. However, relatively few reports have investigated patients treated with daclatasvir. This study described the real-life experience of using sofosbuvir-daclatasvir to treat HCV infection in Chinese KTRs. In total, 100% of the patients achieved SVR12. Adverse events (diarrhea, fatigue, headache, and rash) were reported in 4 patients. These events were mild in severity and resolved spontaneously within a week without treatment. Additionally, significant amelioration of proteinuria after therapy was observed in the group of patients with proteinuria greater than 0.3 g/g. The outcomes were also compared between patients coinfected with or without HBV infection. This report is the first to describe the efficacy of DAAs in this specific population.
The results of this study were consistent with those described recently. Beinhard et al reported a 100% SVR12/24 rate in 13
KTRs taking a full dose of sofosbuvir-daclatasvir. 10 Fernandez and colleagues recently demonstrated high efficacy and good tolerance in KTRs receiving sofosbuvir-ledipasvir (n = 59) and sofosbuvir-daclatasvir (n = 18) with a SVR12 rate of 98%. In that study, half of the patients required immunosuppression dose adjustment. 11 Gentil and colleagues conducted a prospective and retrospective observational study to evaluate the safety and efficacy of DAAs in 119 Spanish KTRs. Among them, 15 patients were treated with sofosbuvir-daclatasvir. A 97.8% SVR12 rate was achieved, and relevant adverse events (ie, anemia, gastrointestinal events, or a minimal increase in the serum creatinine concentration) were reported in 23.5% of the patients. 12 Kamar 14 Consistent with these results, the present study also reported a notable decline in the liver enzyme levels during and after anti-HCV therapy.
The impact of DAA therapy on proteinuria is controversial.
Lubetzky and colleagues noted worsening proteinuria and a decline in the eGFR in KTRs after completing sofosbuvir-ledipasvir therapy. 13 They also compared the sofosbuvir-ledipasvir group with those who were not treated with DAAs and found that proteinuria worsened only in patients in the DAA treatment group.
Kamar et al also examined proteinuria in their study and found 6 patients with proteinuria at baseline. However, proteinuria in this subgroup remained unchanged after therapy. 14 Recently, 
